Eribulin mesylate in the management of metastatic breast cancer and other solid cancers: a drug review.

Abstract	In the new era of 'precision' cancer medicine, new drug development has shifted from cytotoxic chemotherapy to molecularly targeted agents. Eribulin mesylate, a microtubule-destabilizing agent, is the only 'classical' cytotoxic agent approved for the treatment of breast cancer in the last 7 years. This synthetic analogue of halichondrin B, isolated from the marine sponge 'Halicondria Okaida', was responsible for prolonging overall survival of heavily pretreated metastatic breast cancer patients in a large Phase III trial. Eribulin is now under clinical development in earlier settings such as the neo-adjuvant and adjuvant settings. Furthermore, its unique mechanism of action and the absence of cross-resistance with taxanes have led to the design of clinical trials in multiple indications: bladder cancer, lung cancer, prostate cancer… The main adverse events are neutropenia, fatigue and peripheral neuropathy.
Authors	Laura Polastro, Philippe G Aftimos, Ahmad Awada
Journal	Expert review of anticancer therapy (Expert Rev Anticancer Ther) Vol. 14 Issue 6 Pg. 649-65 (Jun 2014) ISSN: 1744-8328 [Electronic] England
PMID	24852360 (Publication Type: Journal Article, Review)
Chemical References	Antineoplastic Agents Drugs, Investigational Ethers, Cyclic Furans Ketones Macrolides Tubulin Modulators halichondrin B eribulin
Topics	Alopecia (chemically induced) Antineoplastic Agents (adverse effects, pharmacology, therapeutic use) Breast Neoplasms (drug therapy) Carcinoma (drug therapy, secondary) Chemotherapy, Adjuvant Clinical Trials as Topic Drug Approval Drug Resistance, Neoplasm Drugs, Investigational Ethers, Cyclic (pharmacology) Fatigue (chemically induced) Female Furans (adverse effects, chemistry, pharmacology, therapeutic use) Humans Ketones (adverse effects, chemistry, pharmacology, therapeutic use) Macrolides (pharmacology) Molecular Targeted Therapy Multicenter Studies as Topic Neoadjuvant Therapy Neutropenia (chemically induced) Peripheral Nervous System Diseases (chemically induced) Tubulin Modulators (adverse effects, chemistry, pharmacology, therapeutic use) United States United States Food and Drug Administration

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!